EDMP Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

EDMP Inc’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,333	Closed	-$202K	–	71
2025 Q1	$202K	Buy	+8,333	New	+$188K	0.17%	70

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EDMP Inc's CPRX Position: Q2 2025 in Review

EDMP Inc sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 8,333 shares — an estimated $202K sold.

EDMP Inc first reported a position in CPRX in Q1 2025 and held it in 1 quarter. The position peaked at $202K in Q1 2025. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

EDMP Inc reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
EDMP Inc sold 8,333 Catalyst Pharmaceutical shares in Q2 2025, an estimated $202K.
EDMP Inc first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 1 quarter.
EDMP Inc's Catalyst Pharmaceutical position peaked at $202K in Q1 2025.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on EDMP Inc's 13F filing for Q2 2025, filed 28 Jul 2025.